DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $1,789,000 | -11.0% | 6,099 | -0.2% | 0.41% | -6.4% |
| Q4 2021 | $2,011,000 | +8.3% | 6,113 | +0.2% | 0.44% | +9.8% |
| Q3 2021 | $1,857,000 | +99.7% | 6,099 | +47.6% | 0.40% | +71.6% |
| Q1 2021 | $930,000 | +1.3% | 4,133 | 0.0% | 0.23% | -9.7% |
| Q4 2020 | $918,000 | +3.5% | 4,133 | +0.3% | 0.26% | -10.5% |
| Q3 2020 | $887,000 | +22.5% | 4,119 | +0.7% | 0.29% | +12.1% |
| Q2 2020 | $724,000 | +28.8% | 4,092 | +0.8% | 0.26% | +3.2% |
| Q1 2020 | $562,000 | +82.5% | 4,060 | +102.2% | 0.25% | +129.6% |
| Q4 2019 | $308,000 | +6.2% | 2,008 | 0.0% | 0.11% | +3.8% |
| Q3 2019 | $290,000 | +1.0% | 2,008 | 0.0% | 0.10% | -1.9% |
| Q2 2019 | $287,000 | +1.4% | 2,008 | -6.5% | 0.11% | +1.9% |
| Q1 2019 | $283,000 | +28.1% | 2,147 | 0.0% | 0.10% | +6.1% |
| Q4 2018 | $221,000 | -5.6% | 2,147 | -0.2% | 0.10% | +6.5% |
| Q3 2018 | $234,000 | +6.4% | 2,152 | -3.7% | 0.09% | -1.1% |
| Q2 2018 | $220,000 | +0.5% | 2,234 | 0.0% | 0.09% | +5.7% |
| Q1 2018 | $219,000 | +20.3% | 2,234 | +3.8% | 0.09% | +3.5% |
| Q2 2017 | $182,000 | – | 2,152 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |